Vaxcyte Inc.

Clinical-stage vaccine innovator using its XpressCF cell-free protein synthesis platform to build a potential best-in-class pneumococcal conjugate vaccine (PCV) franchise. Lead candidate VAX-31, a 31-valent PCV, has completed enrollment in the OPUS-1 Phase 3 adult trial (topline expected Q4 2026) and is in a Phase 2 infant dose-finding study, alongside VAX-24, VAX-XL, and novel Group A Strep (VAX-A1) and Shigella (VAX-GI) protein vaccines.